Physician profile
Jared Hassler
NPI 1821356577
$41,969.11
in general payments reported to CMS, 2019-2025
7 companies · $5,448 in 2025
The $5,448 reported for 2025 was more than what 86% of Anatomic Pathology providers received nationally (typical 2025 total: $110).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $3,342 · 2023: $5,549 · 2024: $28K · 2025: $5,448.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $34K · Travel and Lodging: $3,246 · Food and Beverage: $1,749.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $33,632.00 |
| Travel and Lodging | $3,246.27 |
| Food and Beverage | $1,749.33 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $13,893.42 | 2024-2025 | |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $12,163.50 | 2024-2025 | |
| Novartis Pharmaceuticals Corporation | $5,930.75 | 2023-2025 | |
| Travere Therapeutics, INC. | $5,431.49 | 2020-2025 | |
| Alexion Pharmaceuticals, INC. | $4,507.73 | 2024-2025 | |
| Viiv Healthcare Company | $26.57 | 2024 | Rukobia |
| Werfen USA LLC | $15.65 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jared Hassler listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.